Parlodel is a dopamine receptor stimulant. Parlodel inhibits the secretion of the anterior pituitary hormone - prolactin - without affecting the levels of other pituitary hormones, if they are within normal range. However, it can reduce elevated levels of growth hormone (STH = somatotropic hormone) in patients with acromegaly. This action is due to the stimulation of dopamine receptors. In the postpartum period, prolactin is necessary to start and maintain lactation. In other life periods, increased prolactin secretion leads to pathological lactation (galactorrhea) and/or ovulation and menstrual disorders. Parlodel, as a specific prolactin secretion inhibitor, can be used to prevent or suppress physiological lactation, as well as to treat pathological conditions caused by prolactin hyper-secretion. In amenorrhea and/or anovulatory menstrual cycles (with or without galactorrhea), Parlodel may be used to restore the menstrual cycle and ovulation.
How to use: Dosage and treatment
Inside, during meals, the maximum daily dose is 100 mg.
Menses of the menstrual cycle, female infertility - 1.25 mg 2-3 times a day; if the effect is insufficient, the dose is gradually increased to 5-7.5 mg/day (the frequency of intake 2-3 times a day). Treatment continues until the menstrual cycle is normalized and/or ovulation is restored. If necessary, treatment can be continued for several cycles to prevent relapses.
Premenstrual syndrome - treatment begins on the 14th day of the cycle with 1.25 mg/day. Gradually increase the dose by 1.25 mg/day to 5 mg/day (before menstruation).
Hyperprolactinemia in men - 1.25 mg 2-3 times a day, gradually increasing the dose to 5-10 mg/day.
Prolactinomas - 1.25 mg 2-3 times a day, with a gradual increase in dose to several tablets per day, necessary to maintain an adequate decrease in the concentration of prolactin in the plasma.
Acromegaly - the initial dose is 1.25 mg 2-3 times a day, then, depending on the clinical effect and side effects, the daily dose is gradually increased to 10-20 mg.
Suppression of lactation - 1.25 mg 2 times a day (during meals at breakfast and dinner), then for 14 days - 2.5 mg 2 times a day. To prevent the start of lactation, the medication should be started a few hours after delivery or abortion (after stabilizing vital functions). Sometimes there is a slight secretion of milk 2-3 days after withdrawal. It can be eliminated by resuming the drug in the same dose for another 1 week.
Postpartum loading of mammary glands - prescribed once in a dose of 2.5 mg, after 6-12 hours if necessary, repeat the use (this is not accompanied by undesirable suppression of lactation).
Starting postpartum mastitis - dosing mode is the same as in the case of suppression of lactation. If necessary, an antibiotic is added to the treatment.
Benign breast diseases - 1.25 mg 2-3 times a day. The daily dose is gradually increased up to 5-7.5 mg.
Parkinson's disease - to ensure optimal tolerability, treatment should start with a small dose of the drug: 1.25 mg once a day (preferably in the evening) for 1 week. The daily dose of the drug is increased gradually, every week by 1.25 mg; the daily dose is divided into 2-3 doses. An adequate therapeutic outcome can be achieved within 6-8 weeks of treatment. If this is not the case, the daily dose can be increased further by 2.5 mg/day per week. Average therapeutic doses of bromocriptine for mono or combination therapy are 10-40 mg/day, but some patients may require higher doses. If side effects occur in dose selection, the daily dose should be reduced and maintained at a lower level for at least 1 week. If the side effects disappear, the dose can be increased again. Patients with motor disorders occurring during levodopa administration should reduce the levodopa dose before using bromocriptine. Once a satisfactory effect has been achieved, a further gradual reduction of the levodopa dose can be undertaken. Some patients may have a complete abolition of levodopa.